Key Stats for LLY Stock
- Past week’s performance: +1.2%
- 52-week range: $712 to $1,293
- Valuation model target price: $1,751
- Implied upside: 57% over 2.3 years
Gauge how Lilly’s new pipeline bets compare to its GLP-1 engine (It’s free) >>>
Lilly Bets Beyond Obesity With a New Mental-Health Deal
Eli Lilly and Company (LLY) completed its roughly $2.8 billion acquisition of AtaiBeckley on September 11. The deal adds a pipeline of rapid-acting neuroplastogens aimed at treatment-resistant depression. Its lead program, BPL-003, is designed to work faster than traditional antidepressants and without daily dosing. AtaiBeckley shareholders received cash upfront plus a contingent payment tied to future milestones.
The bigger story, according to Bloomberg, is that Lilly plans to use cash from its GLP-1 franchise to fund a broader push into women’s health. Mounjaro and Zepbound would supply that funding. This marks a meaningful diversification for a company whose stock has been driven almost entirely by obesity and diabetes drugs over the past two years.
Lilly Neuroscience president Carole Ho said the AtaiBeckley pipeline has “the potential to open a new paradigm of treatment,” since it moves away from chronic daily dosing. Millions of patients with treatment-resistant depression are still searching for relief, she added, even after multiple treatment attempts.
If LLY stock keeps compounding while management diversifies its pipeline, the market may eventually stop pricing Lilly purely as a GLP-1 story.
Trace how Lilly’s pipeline expansion could reshape its growth story (It’s free) >>>
Why the Market Still Isn’t Pricing in Lilly’s Full Growth Story
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue Growth (CAGR): 20.3%
- Operating Margins: 49.9%
- Exit P/E Multiple: 27.4x
The model estimates a target price of $1,751, implying a 57% total return and an annualized return of 21.6% over the next 2.3 years.
Lilly’s valuation case leans on continued GLP-1 dominance alongside a widening pipeline. A 20.3% revenue-growth assumption is aggressive for a company already generating tens of billions in annual sales. Mounjaro and Zepbound demand, though, has consistently outpaced expectations.
Margins are the standout figure. A 49.9% operating-margin assumption reflects Lilly’s pricing power and manufacturing scale. Both have improved as new capacity comes online, and that level of profitability is rare among large pharmaceutical companies.
At 27.4x exit earnings, the stock is not cheap, but it is not stretched relative to its own recent history either. The pipeline has expanded through deals in vaccines, oncology, and now mental health. Compared with Novo Nordisk, its closest GLP-1 rival, Lilly trades at a similar premium with a broader portfolio behind it.
The main risk is competitive. Novo Nordisk keeps launching new formulations, and compounded tirzepatide remains a legal headache Lilly is actively fighting. If GLP-1 growth decelerates faster than the new pipeline ramps, that growth assumption would need to come down.
Stack Lilly against Novo Nordisk on growth and margins (Free with TIKR) >>>
Lilly vs. Novo Nordisk: Who Owns the GLP-1 Decade
Novo Nordisk (NVO) remains Lilly’s most direct competitor in weight loss and diabetes care. Novo recently launched its Wegovy pill in Germany. Lilly’s own oral GLP-1, orforglipron, is already available in the United States under the brand Foundayo, giving Lilly a head start in the fast-growing oral segment.
On profitability, Lilly’s roughly 50% operating-margin assumption compares favorably with Novo Nordisk. Novo has faced pressure this year after Morgan Stanley cut its rating on growth and patent-expiry concerns. Amgen (AMGN), a smaller player pushing into obesity, trades at a far lower multiple, reflecting its earlier stage and lower margins.
Lilly’s edge is breadth. Beyond obesity, its neuroscience, oncology, and now women’s health pipelines give it multiple paths to growth. A more concentrated Novo Nordisk does not have that same breadth.
What’s Driving LLY Stock Going Forward?
Lilly’s next earnings report lands October 29. Investors will watch Mounjaro and Zepbound volume trends alongside early sales data for Foundayo, the company’s oral GLP-1 pill.
The Medicare obesity-drug pilot is another catalyst. More than 600,000 seniors have already signed up for coverage through the new program, and broader government or employer coverage would meaningfully expand the addressable market for Lilly’s weight-loss portfolio.
On the legal side, Lilly has filed six lawsuits against U.S. sellers of black-market retatrutide, its next-generation weight-loss compound still in trials. Protecting pricing and safety around that pipeline matters, since retatrutide has shown some of Lilly’s strongest trial results yet.
Going forward, the combination of GLP-1 execution, oral-drug adoption, and new mental-health and women’s health pipelines gives Lilly several distinct growth levers into 2027. If even a few of those bets land, today’s valuation could look conservative.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Eli Lilly?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up LLY, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track LLY alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze LLY stock on TIKR Free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
